MaxCyte Inc. (MXCT)
MaxCyte Statistics
Share Statistics
MaxCyte has 105.48M shares outstanding. The number of shares has increased by 1.3% in one year.
Shares Outstanding | 105.48M |
Shares Change (YoY) | 1.3% |
Shares Change (QoQ) | 0.37% |
Owned by Institutions (%) | 65.4% |
Shares Floating | 97.35M |
Failed to Deliver (FTD) Shares | 1.07K |
FTD / Avg. Volume | 0.2% |
Short Selling Information
The latest short interest is 3M, so 2.85% of the outstanding shares have been sold short.
Short Interest | 3M |
Short % of Shares Out | 2.85% |
Short % of Float | 3.08% |
Short Ratio (days to cover) | 5.59 |
Valuation Ratios
The PE ratio is -12.8 and the forward PE ratio is -12.66. MaxCyte's PEG ratio is -0.14.
PE Ratio | -12.8 |
Forward PE | -12.66 |
PS Ratio | 11.76 |
Forward PS | 2.8 |
PB Ratio | 2.09 |
P/FCF Ratio | -19.12 |
PEG Ratio | -0.14 |
Enterprise Valuation
MaxCyte Inc. has an Enterprise Value (EV) of 457.6M.
EV / Earnings | -12.07 |
EV / Sales | 11.08 |
EV / EBITDA | -10.37 |
EV / EBIT | -9.47 |
EV / FCF | -18.03 |
Financial Position
The company has a current ratio of 10.65, with a Debt / Equity ratio of 0.08.
Current Ratio | 10.65 |
Quick Ratio | 9.97 |
Debt / Equity | 0.08 |
Total Debt / Capitalization | 7.47 |
Cash Flow / Debt | -1.16 |
Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.16% and return on capital (ROIC) is -19.25%.
Return on Equity (ROE) | -0.16% |
Return on Assets (ROA) | -0.14% |
Return on Capital (ROIC) | -19.25% |
Revenue Per Employee | $288,727.27 |
Profits Per Employee | $-265,195.8 |
Employee Count | 143 |
Asset Turnover | 0.15 |
Inventory Turnover | 0.39 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -26.98% in the last 52 weeks. The beta is 1.19, so MaxCyte's price volatility has been higher than the market average.
Beta | 1.19 |
52-Week Price Change | -26.98% |
50-Day Moving Average | 4.29 |
200-Day Moving Average | 4.15 |
Relative Strength Index (RSI) | 28.44 |
Average Volume (20 Days) | 535.99K |
Income Statement
In the last 12 months, MaxCyte had revenue of 41.29M and earned -37.92M in profits. Earnings per share was -0.37.
Revenue | 41.29M |
Gross Profit | 36.55M |
Operating Income | -48.3M |
Net Income | -37.92M |
EBITDA | -44.13M |
EBIT | -48.3M |
Earnings Per Share (EPS) | -0.37 |
Balance Sheet
The company has 46.51M in cash and 18.74M in debt, giving a net cash position of 27.76M.
Cash & Cash Equivalents | 46.51M |
Total Debt | 18.74M |
Net Cash | 27.76M |
Retained Earnings | -175.8M |
Total Assets | 248.61M |
Working Capital | 155.29M |
Cash Flow
In the last 12 months, operating cash flow was -21.69M and capital expenditures -3.7M, giving a free cash flow of -25.39M.
Operating Cash Flow | -21.69M |
Capital Expenditures | -3.7M |
Free Cash Flow | -25.39M |
FCF Per Share | -0.25 |
Margins
Gross margin is 88.51%, with operating and profit margins of -116.98% and -91.85%.
Gross Margin | 88.51% |
Operating Margin | -116.98% |
Pretax Margin | -91.85% |
Profit Margin | -91.85% |
EBITDA Margin | -106.88% |
EBIT Margin | -116.98% |
FCF Margin | -61.49% |
Dividends & Yields
MXCT does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -10.85% |
FCF Yield | -7.06% |
Analyst Forecast
The average price target for MXCT is $9.5, which is 178.6% higher than the current price. The consensus rating is "Buy".
Price Target | $9.5 |
Price Target Difference | 178.6% |
Analyst Consensus | Buy |
Analyst Count | 2 |
Scores
Altman Z-Score | 5.62 |
Piotroski F-Score | 2 |